Topical delgocitinib in severe chronic hand eczema: an alternative to systemic therapy with practical considerations and economic impact
Clicks: 2
ID: 315075
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #157 of 172 articles by views in clinical and experimental dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 172 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Chronic hand eczema can cause major functional and occupational impairment and may be difficult to manage when systemic therapies are contraindicated. We report real-world use of topical delgocitinib in severe, treatment-refractory disease, demonstrating rapid clinical improvement, return to work, and reduced monitoring burden compared with systemic therapy. This case series experience supports topical delgocitinib as an effective and practical therapeutic option in selected patients.
| Reference Key |
openalex_W7162552942
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Emily House, Anna B Chapman |
| Journal | clinical and experimental dermatology |
| Year | 2026 |
| DOI |
10.1093/ced/llag212
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.